Dr. Janet Dancey

Dr. Janet Dancey

Canadian oncologist

Dr. Dancey is Director, Canadian Cancer Trials Group (CCTG) and Scientific Director of the Canadian  Cancer Clinical Trials Network (3CTN) and Senior Investigator, Melanoma Disease Site Committee for  CCTG, and Professor, Department of Oncology, Queen’s University. Previously, she was Program Leader  for High Impact Clinical Trials, Ontario Institute for Cancer Research, Director, Clinical Translational  Research and Chair, Cancer Care Ontario Experimental Therapeutics Network. From 1999-2008, she was  senior investigator and rose to Associate Chief in the Investigational Drug Branch of the Cancer Therapy  Evaluation Program of the National Cancer Institute, United States. She completed medical school at the  University of Ottawa in 1988. She received certifications in internal medicine and medical oncology from  the Royal College of Physicians and Surgeons of Canada in 1992 and 1993 respectively. She has  completed research fellowships at the CCTG (Formerly the NCIC Clinical Trials Group NCIC CTG) and at  the Institut Gustave Roussy, Villejuif, France. 

In her current position, Dr. Dancey is responsible for the strategic development and operational  oversight of programs within CCTG and 3CTN. Her clinical focus is on melanoma and gastrointestinal  malignancies. Key accomplishments included the development and implementation of the CCTG  strategic plan, establishment of the High Impact Clinical Trial Program following successful international  peer review, and the development of novel trials to evaluate investigational drugs in rare tumour  settings, to evaluate next- generation sequencing technologies in cancer patient management. As  Leader of the 3CTN, she is responsible that the network member trial staff and institutions have  resources to rapidly initiate and conduct cancer clinical trials including those with complex biospecimen  and imaging collections. 

Dr. Dancey has expertise in methodologies related to the development, implementation and analysis of  phase I, II, and III studies of cancer therapeutics and in the measurement of quality of life in cancer  trials. She has been a co-investigator, principal investigator and study chair of institutional, industry, and  Canadian cooperative group phase 1 and 2 trials and on CCTG and OICR program grants. 

Dr. Dancey has presented at national and international oncology meetings and has been an invited  speaker at other cancer centres and CME events. She is a member of the Editorial Board of PDQ. She  is/has been an ad hoc reviewer for peer reviewed journals such as the Lancet, Journal of Clinical  Oncology, Journal of the National Cancer Institute, Proceedings of the National Academy of Science  (USA), Clinical Cancer Research, Cancer Research, Cancer Chemotherapy and Pharmacology, Cell  Differentiation and Bone Marrow Transplantation. She has been a member of multiple national and  international scientific peer-review panels and meeting program committees. Dr. Dancey has been the  recipient of awards for excellence in post-graduate teaching from the University of Toronto Department  of Medicine (1994) and Division of Medical Oncology (1997, 1998) and merit awards from the National  Institutes of Health of the United States. 

In addition to being a clinical investigator, Dr. Dancey has worked as a consultant for a number of  pharmaceutical companies in the area of cancer therapeutics development and has assisted in the IND  and registration submissions of new cancer therapeutics to the Health Canada, and the United States  Food and Drug Administration. She is the author or co-author of over 150 peer-reviewed publications,  130 abstracts presented at international meetings in oncology and 20 book chapters in the areas of  oncology therapeutics development, clinical trial methodology patient reported outcomes research, and  treatments for lung and gastrointestinal malignancies.